AVGO
Broadcom Inc.
AVGO has the edge over OSCR overall, supported by stronger modeled upside and lower modeled downside.
OSCR
Oscar Health, Inc.
OSCR's outlook is improving, though it still trails on the overall score.
AVGO Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
AVGO's revenue, profitability, cash flow and balance sheet are all currently strong.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
AVGO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 19x | $364 | — |
| Cheap | 27x | $211 | -42% |
| Current | 46x | $364 | — |
| Fair | 49x | $384 | +5.3% |
| Expensive | 86x | $671 | +84% |
Historical ranges are pointers, not guarantees.
AVGO's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 19x next year's earnings, in its cheap range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over AVGO in the historical PE scenario, which offers more potential upside but is not a forecast.
AVGO Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Stable | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for AVGO, with profitability holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over AVGO on the outlook, with more favorable profitability expectations.
AVGO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $19.23 | +145% |
| Q3 2026 | $7.84 | +100% |
| Q2 2026 | $6.01 | +125% |
| Q1 2026 | $5.13 | +145% |
| Q4 2025 | $4.77 | +288% |
| Q3 2025 | $3.92 | +241% |
| Q2 2025 | $2.67 | +15% |
| Q1 2025 | $2.09 | -23% |
| Q4 2024 | $1.23 | -63% |
AVGO has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
AVGO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $29.6B | +86% |
| Q2 2026 | $22.2B | +48% |
| Q1 2026 | $19.3B | +29% |
| Q4 2025 | $18B | +28% |
| Q3 2025 | $16B | +22% |
| Q2 2025 | $15B | +20% |
| Q1 2025 | $14.9B | +25% |
| Q4 2024 | $14.1B | +51% |
AVGO's revenue has grown year over year every quarter since late 2020: $29.6B last quarter, up 86% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 54% | +17 points |
| Q2 2026 | 49% | +9.8 points |
| Q1 2026 | 44% | +2.4 points |
| Q4 2025 | 42% | +8.8 points |
| Q3 2025 | 37% | +7.9 points |
| Q2 2025 | 39% | +15 points |
| Q1 2025 | 42% | +25 points |
| Q4 2024 | 33% | -13 points |
AVGO has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over AVGO on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
AVGO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $13.7B | +95% |
| Q2 2026 | $10.3B | +60% |
| Q1 2026 | $8B | +33% |
| Q4 2025 | $7.5B | +36% |
| Q3 2025 | $7B | +47% |
| Q2 2025 | $6.4B | +44% |
| Q1 2025 | $6B | +28% |
| Q4 2024 | $5.5B | +16% |
AVGO has the edge over OSCR on cash flow, with more consistent year-over-year improvement.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
AVGO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +11M shares |
| 1 year | +0.6% | +27M shares |
| 3 years | +14% | +617M shares |
| 5 years | +14% | +597M shares |
| Available history | +17% | +697M shares |
AVGO has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $600M |
| Q1 2026 | $7.9B |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | — |
| Q4 2024 | — |
AVGO spent $8.4B buying back its own shares over the past year, about three times what it spent the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
AVGO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 1.2x | Healthy |
| Q1 2026 | 1.7x | Healthy |
| Q4 2025 | 1.9x | Healthy |
| Q3 2025 | 2.3x | Moderate |
| Q2 2025 | 2.7x | Moderate |
| Q1 2025 | 3.1x | Elevated |
| Q4 2024 | 4.1x | High |
AVGO's net debt is less than a year of its operating earnings (EBITDA), down from 2.3 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over AVGO on leverage, with a lower net debt burden relative to earnings.
AVGO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.3 | Neutral |
| Stochastic | 20.3 | Neutral |
AVGO's weekly RSI is 51 (neutral) and its Stochastic is 20 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
AVGO PE vs Technology Sector
| Metric | AVGO | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 28x | 67% above |
| PE % | 47 | 35 | 12 pts above |
AVGO is trading at 46x earnings, a 67% premium to the Technology sector's median of 28x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over AVGO on valuation relative to its sector.
AVGO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $338.0 | 7.8% above |
| 20 week MA | $362.1 | 0.6% above |
| 50 week MA | $363.0 | 0.4% above |
| 100 week MA | $313.8 | 16% above |
| 200 week MA | $214.3 | 70% above |
AVGO is in an uptrend: it's above all five of its weekly moving averages, and 70% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
AVGO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $31.7 | $43.2 | +36% |
| 2021 | $43.2 | $66.5 | +54% |
| 2022 | $66.5 | $55.2 | -17% |
| 2023 | $55.2 | $111.6 | +102% |
| 2024 | $111.6 | $241.8 | +117% |
| 2025 | $241.8 | $352.1 | +46% |
| 2026 YTD | $352.1 | $364.4 | +3.5% |
AVGO has finished higher in five of the last six years, three of them by more than 50%. It's up 3.5% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over AVGO on returns for 2026, with the stronger performance.